Gemcitabine and cisplatin combination chemotherapy in triple negative metastatic breast cancer previously treated with a taxane/anthracycline chemotherapy; Multicenter experience

Neoplasma

Volumn 59, Issue 1, 2012, Pages 38-42

  Ozkan, M ^a   Berk, V ^a   Kaplan, M A ^b   Benekli, M ^c   Coskun, U ^c   Bilici, A ^d   Gumus, M ^d   Alkis, N ^e   Dane, F ^f   Ozdemir, N Y ^g   Colak, D ^h   Dikilitas, M ^a  

^a ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

^b DICLE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^c GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^d Kartal Training and Research Hospital   (Turkey)

^e ANKARA ONCOLOGY HOSPITAL   (Turkey)

^f MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^g ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^h Yildirim Beyazit Training and Research Hospital   (Turkey)

Author keywords

Cisplatin; Gemcitabine; Metastatic breast cancer; Triple negative

Indexed keywords

ANTHRACYCLINE; CISPLATIN; GEMCITABINE; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAXOID;

ADULT; AGED; ANEMIA; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG RESPONSE; FATIGUE; FEMALE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TRIPLE NEGATIVE BREAST CANCER; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; CHEMISTRY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG SCREENING; KAPLAN MEIER METHOD; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; PAGET NIPPLE DISEASE; SALVAGE THERAPY;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG EVALUATION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEUTROPENIA; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SALVAGE THERAPY; TAXOIDS; THROMBOCYTOPENIA;

EID: 84863770666     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2012_005     Document Type: Article

References (20)

1. National Comprehensive Cancer Network. NCCN Practice Guidelines in Oncology-v.1.2009: Breast Cancer. http://www. nccn.org/clinical.asp. Accessed November 2009
2. SASAKI Y, TSUDA H Clinicopathological characteristics of triple-negative breast cancers. Breast Cancer 2009; 16: 254-259. http://dx.doi.org/10.1007/s12282-009-0153-5
3. DOGU GG, OZKAN M, OZTURK F, DIKILITAS M, ER O et al. Triple-negative breast cancer: immunohistochemical correlation with basaloid markers and prognostic value of survivin. Med Oncol. 2010; 27: 34-9. http://dx.doi.org/10.1007/s12032-009-9166-3
4. SPIELMANN M, LLOMBART-CUSSAC A, KALLA S, ESPIE M, NAMER M et al. Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology 2001; 60:3 03-307. http://dx.doi.org/10.1159/000058524
5. BLACKSTEIN M, VOGEL CL, AMBINDER R, COWAN J, IGLESIAS J et al. Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial. Oncology 2002; 62: 2-8. http://dx.doi.org/10.1159/000048240
6. SILVER DP, RICHARDSON AL, EKLUND AC, WANG ZC, SZALLASI Z et al. Efficacy of neoadjuvant Cisplatin in triple negative breast cancer. J Clin Oncol. 2010; 28(7): 1145-53. http://dx.doi.org/10.1200/JCO.2009.22.4725
7. ACHANTA G, PELICANO H, FENG L, PLUNKETT W, HUANG P Interaction of p53 and DNA-PK in response to nucleoside analogues: potential role as a sensor complex for DNA damage. Cancer Res 2001; 61: 8723-8729.
8. PETERS GJ, BERGMAN AM, RUIZ VAN HAPEREN VW, VEERMAN G, KUIPER CM et al. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 1995; 22 (4 Suppl 11): 72-79.
9. HEINEMANN V, STEMMLER HJ, WOHLRAB A, BOSSE D, LOSEM C et al. High efficacy of gemcitabine and cisplatin in patients with predominantly anthracycline-and taxane-pretreated metastatic breast cancer. Cancer Chemother Pharmacol 2006; 57: 640-646. http://dx.doi.org/10.1007/s00280-005-0093-5
10. GIOVANNETTI E, DANESI R, MEY V, NANNIZZI S, PASQUALETTI G et al. In vitro studies on gemcitabine combinations with other antiblastics. Ann Oncol 2006; 17 (Suppl 5): v17-19. http://dx.doi.org/10.1093/annonc/mdj943
11. JASPERS JE, ROTTENBERG S, JONKERS J Therapeutic options for triple-negative breast cancers with defective homologous recombination. Biochim Biophys Acta 2009; 1796: 266-280.
12. UHM JE, PARK YH, YI SY, CHO EY, CHOI YL et al. Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinumcontaining chemotherapy. Int J Cancer 2009; 124: 1457-1462. http://dx.doi.org/10.1002/ijc.24090
13. YI S, UHM J, CHO E, LEE S, PARK M et al. Program and abstracts of the 2008 Annual Meeting of the American Society of Clinical Oncology; abstract 1008.
14. CHIA J. W, ANG P, SEE H, WONG Z, SOH L et al. Program and abstracts of the 2007 Annual Meeting of the American Society of Clinical Oncology; abstract 1086.
15. THOME S, HOBDAY T, HILLMAN D, AUBRY M, LINGLE W et al. Program and abstracts of the 2007 Annual Meeting of the American Society of Clinical Oncology; abstract 1071.
16. HUSAIN A, HE G, VENKATRAMAN ES, SPRIGGS DR BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum (II). Cancer Res 1998; 15: 1120-1123.
17. SCHREIBER V, DANTZER F, AME JC, DE MURCIA G. Poly (ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 2006; 7: 517-528. http://dx.doi.org/10.1038/nrm1963
18. ROTTENBERG S, JASPERS JE, KERSBERGEN A, VAN DER BURG E, NYGREN AO et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA 2008; 105: 17079-84. http://dx.doi.org/10.1073/pnas.0806092105
19. O SHAUGHNESSY J, OSBORNE C, PIPPEN J, YOFFE M, PATT D et al. Final Results of a Randomized Phase II Study Demonstrating Efficacy and Safety of BSI-201, a Poly (ADPRibose) Polymerase (PARP) Inhibitor, in Combination with Gemcitabine/Carboplatin (G/C) in Metastatic Triple Negative Breast Cancer (TNBC). San Antonio Breast Cancer Symposium December 9-13, 2009 San Antonio, Texas, USA. Abstract 3122.
20. J. O'SHAUGHNESSY, L. S. SCHWARTZBERG, M. A. DANSO, H. S. RUGO, K. MILLER et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). Program and abstracts of the 2011 Annual Meeting of the American Society of Clinical Oncology. Abstract No: 1007